Close
4

Quotient Sciences Quotient Sciences

X

Company profile for Promedior

  • Webinars & Exhibitions

PharmaCompass
About the Company
Promedior is a clinical-stage biotechnology company pioneering the development of targeted therapeutics to treat fibrotic diseases. Fibrosis is a process that occurs in many diseases, when normal healthy tissue is replaced with scar tissue, compromising normal function and leading ultimately to organ failure. Promedior’s proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that acts through...
Promedior is a clinical-stage biotechnology company pioneering the development of targeted therapeutics to treat fibrotic diseases. Fibrosis is a process that occurs in many diseases, when normal healthy tissue is replaced with scar tissue, compromising normal function and leading ultimately to organ failure. Promedior’s proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that acts through a unique anti-fibrotic immunotherapy mechanism to activate a regulatory switch upstream in the fibrosis cascade. Promedior has built a strong team experienced in developing, advancing, and commercializing products.

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Send me more info on How To Grow My Bussiness Digitally?
Promedior
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
81 Hartwell Avenue - Suite 100 Lexington, MA 02421
Telephone
Telephone
+1-781.538.4200
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY